AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32726473 — intervention group
Group type: EXPERIMENTAL
Intervention: both interventions
Number of subjects: 412
Study 32490621 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate and NSAIDs (group 1)
Number of subjects: 231
Study 32490621 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs only (group 2)
Number of subjects: 231
Study 35026408 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 84
Study 35026408 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release Quetiapine
Number of subjects: 84
Study 35026408 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole or Extended-release Quetiapine
Number of subjects: 84
Study 35026408 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS-6
Number of subjects: 84
Study 35026408 — intervention group
Group type: EXPERIMENTAL
Intervention: CGI-I
Number of subjects: 84
Study 34806452 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% dextrose water (DW) serum, 8.75 to 18.75 g/kg/d
Number of subjects: 90
Study 34806452 — intervention group
Group type: COMPARATOR
Intervention: 10% dextrose water (DW) serum, 7 to 15 g/kg/d
Number of subjects: 90
Study 35619571 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Occupational Health Coaching (REOHC)
Number of subjects: 0
Study 35619571 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (WLG)
Number of subjects: 0
Study 32620149 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity program with connected devices (activity tracker worn 24/7, at least three weekly walking sessions, quizzes on physical activity and nutrition) for 6 months
Number of subjects: 244
Study 32620149 — intervention group
Group type: COMPARATOR
Intervention: Physical activity recommendations only
Number of subjects: 244
Study 33389132 — intervention group
Group type: EXPERIMENTAL
Intervention: 2/W‐TPTD (28.2‐μg teriparatide formulation for twice‐weekly use)
Number of subjects: 0
Study 33389132 — intervention group
Group type: COMPARATOR
Intervention: 1/W‐TPTD (56.5‐μg teriparatide formulation for once‐weekly use)
Number of subjects: 0
Study 33389132 — intervention group
Group type: EXPERIMENTAL
Intervention: 2/W‐TPTD
Number of subjects: 0
Study 35953409 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative lanreotide (120 mg)
Number of subjects: 98
Study 34362859 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT), ten 50‐minute weekly sessions
Number of subjects: 55
Study 34362859 — intervention group
Group type: COMPARATOR
Intervention: Low‐perfectionist controls
Number of subjects: 55
Study 36147279 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporin A (CsA) 0.05% for 3 months
Number of subjects: 78
Study 36147279 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CsA)
Number of subjects: 78
Study 33683616 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist
Number of subjects: 54
Study 33683616 — intervention group
Group type: COMPARATOR
Intervention: Usual approach (Control)
Number of subjects: 54
Study 33582039 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Health Coaching (DHC)
Number of subjects: 365
Study 33582039 — intervention group
Group type: COMPARATOR
Intervention: Usual Diabetes Education (DE)
Number of subjects: 365
Study 33582039 — intervention group
Group type: EXPERIMENTAL
Intervention: DHC plus DE
Number of subjects: 365
Study 32152146 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein capsules (50 mg/day) for 2 months
Number of subjects: 45
Study 32152146 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 45
Study 35221757 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 120
Study 35221757 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg/kg
Number of subjects: 120
Study 35221757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33156916 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium rMED adherence
Number of subjects: 4896
Study 33156916 — intervention group
Group type: EXPERIMENTAL
Intervention: Low rMED adherence
Number of subjects: 4896
Study 33156916 — intervention group
Group type: EXPERIMENTAL
Intervention: High rMED adherence
Number of subjects: 4896
Study 34301299 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz EA
Number of subjects: 144
Study 34301299 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz EA
Number of subjects: 144
Study 34301299 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 144
Study 32093451 — intervention group
Group type: EXPERIMENTAL
Intervention: Day Surgery Group (DSG)
Number of subjects: 153
Study 32093451 — intervention group
Group type: COMPARATOR
Intervention: Inpatient Surgery Group (ISG)
Number of subjects: 153
Study 33734493 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 40
Study 33734493 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 40
Study 33221391 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise group (MEG)
Number of subjects: 72
Study 33221391 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity exercise group (VEG)
Number of subjects: 72
Study 33221391 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 72
Study 34836135 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching and usual care for 6 months
Number of subjects: 114
Study 34836135 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 114
Study 35841024 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Intervention Treatment (VIT) - includes up to 11 virtual counseling sessions with a tobacco treatment specialist and up to 12 weeks of nicotine replacement therapy (NRT)
Number of subjects: 49
Study 35841024 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Control (EUC) - receives a referral to the NCI Quitline
Number of subjects: 49
Study 34704720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Erector Spinae Plane Blockade (ESPB)
Number of subjects: 52
Study 34704720 — intervention group
Group type: COMPARATOR
Intervention: Placebo subcutaneous injection
Number of subjects: 52
Study 35840999 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month pantoprazole treatment arm
Number of subjects: 232
Study 35840999 — intervention group
Group type: COMPARATOR
Intervention: 1-month pantoprazole treatment arm
Number of subjects: 232
Study 33542089 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental O2 (42%±7%) during exercise
Number of subjects: 15
Study 33542089 — intervention group
Group type: COMPARATOR
Intervention: Medical air during exercise
Number of subjects: 15
Study 32891281 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic meditation (MG) for eight weeks
Number of subjects: 64
Study 35852266 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 180
Study 35852266 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 180
Study 35852266 — intervention group
Group type: COMPARATOR
Intervention: No TENS
Number of subjects: 180
Study 33407407 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program based on Theory of Planned Behavior (TPB) constructs delivered via direct training
Number of subjects: 160
Study 33407407 — intervention group
Group type: COMPARATOR
Intervention: Usual training only (Control)
Number of subjects: 160
Study 33313724 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT) for 6 weeks
Number of subjects: 0
Study 33313724 — intervention group
Group type: EXPERIMENTAL
Intervention: Army Medicine's holistic Move2Health (M2H) program for 6 weeks
Number of subjects: 0
Study 33313724 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined M2H + PT in phase II for nonresponders
Number of subjects: 0
Study 33313724 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Oriented Recovery Enhancement (MORE) program in phase II for nonresponders
Number of subjects: 0
Study 35597252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 149
Study 35597252 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 149
Study 34051350 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Number of subjects: 0
Study 34051350 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity exercise
Number of subjects: 0
Study 33484075 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin (ADPN)
Number of subjects: 0
Study 33484075 — intervention group
Group type: COMPARATOR
Intervention: eGFR
Number of subjects: 0
Study 32112668 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine jugular vein valved xenograft (BJV)
Number of subjects: 206
Study 32112668 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE) tube
Number of subjects: 206
Study 32112668 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 206
Study 34438091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate closure (CAC)
Number of subjects: 126
Study 34438091 — intervention group
Group type: COMPARATOR
Intervention: Surgical stripping (SS)
Number of subjects: 126
Study 33665728 — intervention group
Group type: EXPERIMENTAL
Intervention: WM (bioequivalent formulation)
Number of subjects: 0
Study 33665728 — intervention group
Group type: COMPARATOR
Intervention: GXR (reference product)
Number of subjects: 0
Study 32151851 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker
Number of subjects: 14
Study 32151851 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker
Number of subjects: 14
Study 32151851 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 14
Study 34755388 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian group-sequential trial design utilizing Multisource Exchangeability Models
Number of subjects: 0
Study 34755388 — intervention group
Group type: COMPARATOR
Intervention: Traditional group-sequential design
Number of subjects: 0
Study 34481551 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with sickle cell disease (HbSS and HbSC) born between 2003 and 2013
Number of subjects: 11186
Study 34481551 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with sickle cell disease (HbSS and HbSC)
Number of subjects: 11186
Study 34481551 — intervention group
Group type: COMPARATOR
Intervention: National under-5 mortality
Number of subjects: 11186
Study 32404056 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L‐PEG solutions with 1 L GT liquids
Number of subjects: 116
Study 32404056 — intervention group
Group type: COMPARATOR
Intervention: 2 L‐PEG solutions only
Number of subjects: 116
Study 34732695 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt SSRI treatment with escitalopram 20 mg
Number of subjects: 27
Study 34732695 — intervention group
Group type: COMPARATOR
Intervention: Covert SSRI treatment with escitalopram 20 mg
Number of subjects: 27
Study 34732695 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt SSRI treatment
Number of subjects: 27
Study 34732695 — intervention group
Group type: COMPARATOR
Intervention: Covert SSRI treatment
Number of subjects: 27
Study 34732695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study 34506311 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia strategies for trauma
Number of subjects: 1561
Study 32234702 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical Bayesian regression model using 4 days of self-assessment
Number of subjects: 84
Study 32234702 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical Bayesian regression model
Number of subjects: 84
Study 32234702 — intervention group
Group type: EXPERIMENTAL
Intervention: Forecasting method
Number of subjects: 84
Study 35350537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) intervention including personalized breathing training, small muscle group resistance training, and aerobic endurance training for 5 days.
Number of subjects: 120
Study 35350537 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (no specific intervention details provided).
Number of subjects: 120
Study 35350537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) intervention.
Number of subjects: 120
Study 33867496 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 24
Study 33867496 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 34057186 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention
Number of subjects: 456
Study 34057186 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 456
Study 32041601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensifentrine 0.75 mg
Number of subjects: 405
Study 32041601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensifentrine 1.5 mg
Number of subjects: 405
Study 32041601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensifentrine 3 mg
Number of subjects: 405
Study 32041601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensifentrine 6 mg
Number of subjects: 405
Study 32041601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 32041601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensifentrine (all doses)
Number of subjects: 405
Study 34581219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 1455
Study 34581219 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab plus Bevacizumab
Number of subjects: 1455
Study 34019026 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention group (n = 34)
Number of subjects: 101
Study 34019026 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercise group (n = 32)
Number of subjects: 101
Study 34019026 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 35)
Number of subjects: 101
Study 36054245 — intervention group
Group type: COMPARATOR
Intervention: FiO2 ≥ 0.50 (group H)
Number of subjects: 191
Study 36054245 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 0.21 (group N)
Number of subjects: 191
Study 33906631 — intervention group
Group type: EXPERIMENTAL
Intervention: LOCK sleep intervention
Number of subjects: 27
Study 35225536 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 120
Study 35225536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33612360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose 20 mg/kg
Number of subjects: 102
Study 33612360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 33612360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose
Number of subjects: 102
Study 33612360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 102
Study 32885518 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy (RT) intervention
Number of subjects: 56
Study 32885518 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 56
Study 33499668 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation with pulmonary vein isolation
Number of subjects: 2204
Study 33499668 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy with rate/rhythm control agents
Number of subjects: 2204
Study 33499668 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 2204
Study 33499668 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 2204
Study 32460748 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web-based intervention
Number of subjects: 400
Study 32460748 — intervention group
Group type: COMPARATOR
Intervention: Web-based information without sexual health components
Number of subjects: 400
Study 35793698 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient portal use
Number of subjects: 654
Study 35793698 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient portal use
Number of subjects: 654
Study 35793698 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge portal use assessment
Number of subjects: 654
Study 34191090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 154
Study 34191090 — intervention group
Group type: COMPARATOR
Intervention: No-tourniquet
Number of subjects: 154
Study 32153038 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal Splint (OS)
Number of subjects: 89
Study 32153038 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 89
Study 32153038 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling (CS)
Number of subjects: 89
Study 32153038 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Occlusal Splint and Counselling (OSCS)
Number of subjects: 89
Study 32153038 — intervention group
Group type: COMPARATOR
Intervention: All groups (OS, MT, CS, OSCS)
Number of subjects: 89
Study 34597743 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery of giving 30 M&Ms to children
Number of subjects: 92
Study 34597743 — intervention group
Group type: COMPARATOR
Intervention: Imagery of eating 30 M&Ms
Number of subjects: 92
Study 34597743 — intervention group
Group type: COMPARATOR
Intervention: Imagery of sorting 30 marbles
Number of subjects: 92
Study 35675228 — intervention group
Group type: EXPERIMENTAL
Intervention: Information designed to correct misperceptions of gun owner support for gun safety policies
Number of subjects: 0
Study 35675228 — intervention group
Group type: COMPARATOR
Intervention: Control information
Number of subjects: 0
Study 32813887 — intervention group
Group type: EXPERIMENTAL
Intervention: GRAZAX® (sublingual immunotherapy) for 2 years
Number of subjects: 47
Study 32813887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 35058417 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐guar/nanoemulsion
Number of subjects: 24
Study 35058417 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐guar/HA
Number of subjects: 24
Study 35058417 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 24
Study 33049220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane (TAP) block
Number of subjects: 18
Study 33049220 — intervention group
Group type: COMPARATOR
Intervention: Control group (without TAP block)
Number of subjects: 18
Study 35084724 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol plus budesonide nebulizer (budesonide 0.5 mg nebulized three times for 20 minutes)
Number of subjects: 228
Study 35084724 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol nebulizer alone
Number of subjects: 228
Study 35084724 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol plus budesonide nebulizer
Number of subjects: 228
Study 33572946 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity and Sport for Acquired Brain Injury (PASABI) program (1-hour sessions, 2-4 sessions/week for 18 weeks)
Number of subjects: 73
Study 33572946 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation program without physical activity (Control Group)
Number of subjects: 73
Study 32517453 — intervention group
Group type: EXPERIMENTAL
Intervention: Da Vinci robotic radical lung cancer surgery with chest wall external nursing interventions
Number of subjects: 0
Study 32517453 — intervention group
Group type: EXPERIMENTAL
Intervention: Da Vinci robotic radical lung cancer surgery with chest wall external nursing interventions for patients with chest wall thickness < 4 cm
Number of subjects: 0
Study 32517453 — intervention group
Group type: COMPARATOR
Intervention: Robotic radical lung cancer resection with abdominal bands wrapped around the chest (Control Group)
Number of subjects: 0
Study 35622269 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ZIDA® activation device (ZIDA)
Number of subjects: 40
Study 35622269 — intervention group
Group type: COMPARATOR
Intervention: Sham control group (SCG)
Number of subjects: 40
Study 33272959 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Number of subjects: 190
Study 33272959 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 190
Study 34426445 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly assessment by the GP of 8 geriatric syndromes with a tailored management plan
Number of subjects: 429
Study 34426445 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 429
Study 35415998 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PRO (0.75+0.25g·BW‐1)
Number of subjects: 10
Study 35415998 — intervention group
Group type: COMPARATOR
Intervention: CHO (1.0g·BW‐1)
Number of subjects: 10
Study 35415998 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 10
Study 32319341 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation program based on Human Caring Theory
Number of subjects: 24
Study 32319341 — intervention group
Group type: COMPARATOR
Intervention: Antenatal education classes
Number of subjects: 24
Study 32332464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.1 mg/kg
Number of subjects: 99
Study 32332464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 99
Study 32332464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 99
Study 32332464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1.0 mg/kg
Number of subjects: 99
Study 32332464 — intervention group
Group type: COMPARATOR
Intervention: Active placebo, midazolam 0.045 mg/kg
Number of subjects: 99
Study 32332464 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese category (BMI)
Number of subjects: 99
Study 32332464 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight category (BMI)
Number of subjects: 99
Study 32332464 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference group (not obese/overweight)
Number of subjects: 99
Study 34031723 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual autonomic blockade (DAB) with 0.04 mg/kg atropine and 0.2 mg/kg metoprolol
Number of subjects: 29
Study 34031723 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual autonomic blockade (DAB)
Number of subjects: 29